Assessment of biomarkers in women with endometriosis-associated pain using the ENG contraceptive implant or the 52 mg LNG-IUS: a non-inferiority randomised clinical trial

Autor(es)

Margatho, Deborah ^[1] ; Carvalho, Nelsilene Mota ^[1] ; Eloy, Larissa ^[2] ; Bahamondes, Luis ^[1]

Afiliação do(s) autor(es)

^[1] Univ Estadual Campinas, Dept Obstet & Gynaecol, Med Sch, Caixa Postal 6181, BR-13084971 Campinas, SP - Brazil

^[2] Univ Estadual Campinas, Dept Pathol, Med Sch, Campinas, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE; v. 23, n. 5, p. 344-350, 2018.
• Citações Web of Science: 0

Resumo

Objective: The aim of the study was to assess the serum levels of the following biomarkers in women with endometriosis-associated pelvic pain before and after six months of using the etonogestrel (ENG) contraceptive implant or the 52 mg levonorgestrel-releasing intrauterine system (LNG-IUS): cancer antigen (CA)-125, cluster of differentiation (CD) 23 and endometrial nerve fibre density. Methods: The study was conducted at the Department of Obstetrics and Gynaecology, University of Campinas Medical School, Brazil. A total of 103 women with endometriosis-associated pain diagnosed by surgery, transvaginal ultrasound and/or magnetic resonance imaging were included. Endometrial nerve fibre density and serum levels of CA-125 and soluble CD23 were assessed before and after six months of using the allocated method and were correlated to 10 cm visual analogue scale (VAS) scores for non-cyclical pelvic pain and dysmenorrhoea. Results: Both contraceptive methods significantly reduced concentrations of serum soluble CD23 and endometrial nerve fibre density (p < .001); however, CA-125 was significantly reduced only among users of the ENG implant (p < .05). No correlation was observed between reduction of biomarkers and improvement of VAS pain and dysmenorrhoea scores. No differences were observed between the ENG implant and the LNG-IUS. Conclusion: Both progestin-only contraceptives significantly reduced two out of the three biomarkers evaluated. These two biomarkers could, therefore, be used as surrogate markers to follow up medical treatment of endometriosis-associated pain. (AU)

• Processo FAPESP: 15/20504-9 - Manifestações clínicas de usuárias de contraceptivos de somente progestogênios
• Beneficiário: Luis Guillermo Bahamondes
• Modalidade de apoio: Auxílio à Pesquisa - Temático